



EXPRESS MAIL NO. EV889161122US

Sheet 1 of 1

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE 2 ND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		ATTY. DOCKET NO. 110191.402	APPLICATION NO. 10/718,499
		APPLICANT Nathaniel E. David	
		FILING DATE November 19, 2003	GROUP ART UNIT 3622

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,503,881	01/07/03	Krieger et al.	514	2	
	AB	2005/0108047	05/19/05	David	705	2	
	AC	2006/0111302	05/25/06	Romesberg et al.	514	18	
	AD	2006/0286574	12/21/06	Romesberg et al.	435	6	
	AE						
	AF						
	AG						
	AH						
	AI						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK	2002-114704A	04/16/02	JP (+ Abstract in English)		
	AL					
	AM					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AN	Cirz et al., "Inhibition of Mutation and Combating the Evolution of Antibiotic Resistance," <i>PLoS Biology</i> , 3(6):1024-1033, June 2005.
AO	Cirz, Ryan T., and Floyd E. Romesberg, "Induction and Inhibition of Ciprofloxacin Resistance-Conferring Mutations in Hypermutator Bacteria," <i>Antimicrobial Agents and Chemotherapy</i> , 50(1):220-225, January 2006.
AP	Miyakawa et al., "In Vitro Activity of the Antimicrobial Peptides Human and Rabbit Defensins and Porcine Leukocyte Protegrin Against Mycobacterium Tuberculosis," <i>Infection and Immunity</i> 64(3):926-932, March 1996.
AQ	Yasuda et al., "Inhibition of Escherichia coli RecA Coprotease Activities by Dnl," <i>The EMBO Journal</i> 17(11):3207-3216, June 1, 1998.

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).